Tafamidis for Transthyretin Amyloid Cardiomyopathy
Tafamidis for Transthyretin Amyloid Cardiomyopathy
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
To the Editor:
In reporting the results of the Transthyretin Amyloidosis Cardiomyopathy Clinical Trial (ATTR-ACT), Maurer et al. (Sept. 13 issue)
1
conclude that tafamidis was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations in patients with transthyretin-associated (ATTR) amyloidosis with cardi...
Alternative Titles
Full title
Tafamidis for Transthyretin Amyloid Cardiomyopathy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2179332897
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2179332897
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc1814074
